Drug maker Intas Pharmaceuticals today said it has filed documents with market regulator Sebi for an initial public offer that includes sale of fresh equity worth Rs 425 crore.
"Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) for an initial public offering," the Ahmedabad-based firm said in a statement.
The issue comprises a fresh issue equity shares aggregating up to Rs 425 crore and an offer for sale of 58.1 lakh equity shares by Mozart Ltd.
Kotak Mahindra Capital Company and Morgan Stanley India Company Pvt Ltd are the book running lead managers to the issue.
"Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) for an initial public offering," the Ahmedabad-based firm said in a statement.
The issue comprises a fresh issue equity shares aggregating up to Rs 425 crore and an offer for sale of 58.1 lakh equity shares by Mozart Ltd.
Kotak Mahindra Capital Company and Morgan Stanley India Company Pvt Ltd are the book running lead managers to the issue.
INTAS group is very dishonest when dealing with its
ReplyDeletesenior employees.
Intas Biopharma ltd offered ESOP to all senior employees around 7 years back.Extracted performance
for around 6 years and then suddenly the company dropped the ESOP scheme.The cheated seniors include
Executive director, Director-HR, COO, CEO etc.
the total cheated money will be around Rs 4 crs worth.Some seniors like CEO have filed cases in various courts.Many kept quite due thier current career compulsions.
Beware of INTAS!